VOICI CE QUE L'ON TROUVE SUR LE SITE EMBO MOLLECULAR MEDICINE
Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin
Guilherme Dias de MeloFrançoise LazariniFlorence LarrousLena FeigeEtienne KornobisSylvain LevalloisAgnès MarchioLauriane KergoatDavid HardyThomas CokelaerPascal PineauMarc LecuitPierre-Marie LledoJean-Pierre ChangeuxHervé Bourhy
VOICI LE RESUME QUE LES AUTEURS PROPOSENT
Results
We report that ivermectin, used at the standard anti-parasitic dose of 400 µg/kg, protects infected hamsters from developing clinical signs and from losing the sense of smell during SARS-CoV-2 infection. The treated animals exhibited a specific inflammatory response, presenting a reduced type I/III interferon stimulation and a modulation in several intracellular signaling pathways, with an important reduction of the Il-6/Il-10 ratio and promoting M2 polarization of myeloid cells recruited to the lung. These effects are strongly influenced by sex, with treated females exhibiting the best outcome. Surprisingly, ivermectin treatment did not limit viral replication, as treated and non-treated animals presented similar amounts of SARS-CoV-2 in the nasal cavity and in the lungs.
Impact
The results of this study establish that irrespective of viral load, the symptoms and severity of COVID-19 highlight the critical role played by host inflammatory response in COVID-19 severity and highlight that reduced type I/III interferon and Il-6/Il-10 and the presence of M2 macrophages might account for a more favorable clinical presentation, contributing to a better understanding of COVID-19 pathophysiology. Ivermectin might then be considered as promising therapeutic agent against COVID-19 with no impact on SARS-CoV-2 replication but alleviating inflammation and ensuing symptoms.
Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin
Guilherme Dias de MeloFrançoise LazariniFlorence LarrousLena FeigeEtienne KornobisSylvain LevalloisAgnès MarchioLauriane KergoatDavid HardyThomas CokelaerPascal PineauMarc LecuitPierre-Marie LledoJean-Pierre ChangeuxHervé Bourhy
VOICI LE RESUME QUE LES AUTEURS PROPOSENT
Results
We report that ivermectin, used at the standard anti-parasitic dose of 400 µg/kg, protects infected hamsters from developing clinical signs and from losing the sense of smell during SARS-CoV-2 infection. The treated animals exhibited a specific inflammatory response, presenting a reduced type I/III interferon stimulation and a modulation in several intracellular signaling pathways, with an important reduction of the Il-6/Il-10 ratio and promoting M2 polarization of myeloid cells recruited to the lung. These effects are strongly influenced by sex, with treated females exhibiting the best outcome. Surprisingly, ivermectin treatment did not limit viral replication, as treated and non-treated animals presented similar amounts of SARS-CoV-2 in the nasal cavity and in the lungs.
Impact
The results of this study establish that irrespective of viral load, the symptoms and severity of COVID-19 highlight the critical role played by host inflammatory response in COVID-19 severity and highlight that reduced type I/III interferon and Il-6/Il-10 and the presence of M2 macrophages might account for a more favorable clinical presentation, contributing to a better understanding of COVID-19 pathophysiology. Ivermectin might then be considered as promising therapeutic agent against COVID-19 with no impact on SARS-CoV-2 replication but alleviating inflammation and ensuing symptoms.
